person · Reporting owner
WOODGRIFT RANDEL WILLIAM
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 52,203 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 4,123 · Balance 53,235 Row 2 · 2023-03-01 · Sale · Disposed 1,032 · Balance 52,203 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 3,495 |
Reported balance
Holding disclosure · report date 2023-02-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,495 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 01:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,032 | $100.70 | $103,922.40 |
DisclosureSEC source: 0001415889-23-003926 · form4-03032023_010311.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,203 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 01:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,123 | $99.77 | $411,351.71 |
DisclosureSEC source: 0001415889-23-003926 · form4-03032023_010311.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,235 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 37,483 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003077 · form4-02232023_120232.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,483 Underlying: Common Shares · 37,483 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003077 · form4-02232023_120232.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,358 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| May 04, 2022 Filed May 5, 2022 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 24,000 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-22-004697 · form4-05052022_030522.xml · derivative · entry 4 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,271 Underlying: Common Shares · 24,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 04, 2022 Filed May 5, 2022 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 24,000 | $113.00 | $2,712,103.20 |
DisclosureSEC source: 0001415889-22-004697 · form4-05052022_030522.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,854 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.00 to $113.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 04, 2022 Filed May 5, 2022 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 24,000 | $44.40 | $1,065,600.00 |
DisclosureSEC source: 0001415889-22-004697 · form4-05052022_030522.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,369 | $118.36 | $162,034.84 |
DisclosureSEC source: 0001415889-22-003847 · form4-04052022_020419.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,854 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 01:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 964 | $118.10 | $113,849.36 |
DisclosureSEC source: 0001415889-22-002206 · form4-03022022_050349.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,223 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,038 | $122.41 | $494,291.58 |
DisclosureSEC source: 0001415889-22-002206 · form4-03022022_050349.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,187 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 48,852 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001750 · form4-02232022_050209.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,852 Underlying: Common Shares · 48,852 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024, and 16,284 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001750 · form4-02232022_050209.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,225 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · derivative · entry 5 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Shares · 1,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,350 | $129.00 | $690,150.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · nonDerivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,743 Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $129.00 | $129,000.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,093 Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,000 | $38.40 | $38,400.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,368 | $119.84 | $163,941.12 |
DisclosureSEC source: 0001415889-21-001834 · form4-04022021_020400.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,093 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,034 | $120.61 | $124,710.74 |
DisclosureSEC source: 0001415889-21-001218 · form4-03022021_050317.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,461 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,135 | $121.58 | $502,733.30 |
DisclosureSEC source: 0001415889-21-001218 · form4-03022021_050317.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,495 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 47,993 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000905 · form4-02232021_040255.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Underlying: Common Shares · 47,993 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,997 on February 19, 2022, 15,998 on February 19, 2023, and 15,998 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000905 · form4-02232021_040255.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,630 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $105.28 | $263,200.00 |
DisclosureSEC source: 0001179110-20-009786 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,267 Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,724 | $93.18 | $347,012.37 |
DisclosureSEC source: 0001179110-20-005291 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,767 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.17 to $93.274, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,368 | $78.91 | $107,948.88 |
DisclosureSEC source: 0001179110-20-004687 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,491 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,420 | $77.89 | $110,603.80 |
DisclosureSEC source: 0001179110-20-002918 · edgar.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,859 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,533 | $79.19 | $279,778.27 |
DisclosureSEC source: 0001179110-20-002918 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,279 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 68,578 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002283 · edgar.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,578 Underlying: Common shares · 68,578 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,859 on February 21, 2021, 22,859 on February 21, 2022, and 22,860 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002283 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,812 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 16,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · derivative · entry 5 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Underlying: Common shares · 16,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,000 | $80.60 | $403,000.00 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · nonDerivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,562 Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 16,000 | $80.52 | $1,288,315.20 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,562 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.41 to $80.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 16,000 | $38.40 | $614,400.00 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2019 Filed Jul 27, 2019 01:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001104659-19-042123 · a4.xml · derivative · entry 4 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common shares · 65,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 24, 2019 Filed Jul 27, 2019 01:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 65,000 | $88.01 | $5,720,325.00 |
DisclosureSEC source: 0001104659-19-042123 · a4.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,562 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 24, 2019 Filed Jul 27, 2019 01:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 65,000 | $38.40 | $2,496,000.00 |
DisclosureSEC source: 0001104659-19-042123 · a4.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,000 | $73.40 | $146,798.20 |
DisclosureSEC source: 0001179110-19-005145 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,562 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 43,388 | $79.98 Strike: $79.98 | $3,470,172.24 |
DisclosureSEC source: 0001179110-19-004731 · edgar.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,388 Underlying: Common shares · 43,388 shares Expires 2029-03-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,462 on April 1, 2020, 14,463 on April 1, 2021, and 14,463 on April 1, 2022. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 8,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004731 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.